Articles tagged with Breast Cancer
A national study found digital mammography performed better than film in pre- and perimenopausal women under 50 with dense breasts. The study, DMIST, also showed improved diagnostic accuracy for digital mammography over film for some subgroups.
Two microRNAs, miR-373 and miR-520c, have been identified as promoting the spread of tumor cells. The study found that miR-373 is a potential biomarker for metastatic breast cancer and may be used to develop new treatments.
The PEM/PET system can spot tumors half the size of standard imaging systems, and complete an image and biopsy in a similar time frame. It features high-resolution PET images of the breast, guiding needle biopsies with a robot arm.
A study of 227 breast cancer patients found that those who participated in a psychological intervention program had better health and functioning scores, with a 7% increase compared to non-participants. The program included training on relaxation, coping with stress, and strategies for improving health behaviors, resulting in fewer sym...
A study by Brown University and Harvard Medical School found that health insurance co-payments significantly reduce mammography use among women. The researchers analyzed data from Medicare managed-care plans and found a 8-11% decrease in breast cancer screening rates among women with co-payments, compared to those with full coverage.
A study found surgical site infections in 5.3% of patients following breast surgery, with higher costs and longer hospital stays for infected patients. The cost of surgical site infections was estimated at $4,091 per patient.
Researchers at Duke University Medical Center have identified a new pathway involving BRCA1 in repairing damaged DNA, which may explain the increased breast cancer risk in women with mutated BRCA1 genes. This discovery could lead to more effective therapies for women with and without BRCA1 mutations.
Researchers have identified cyclin D1 as a key player in ER+ breast cancers, which are the most common type of breast cancer. The study found that inhibiting cyclin D1 function may provide a new treatment strategy for these tumors.
Postmenopausal women taking combined estrogen/progestin hormone-replacement therapy for three years or more face a significant increased risk of developing various forms of lobular breast cancer. The study, which confirms previous reports, suggests that even short exposure to such hormones may confer an increased risk.
Researchers have identified specific protein markers in human saliva that can provide an early, non-invasive diagnosis of breast cancer. The study found 49 proteins that differentiated healthy patients from those with benign and malignant breast tumors.
The Joni Gladowsky Breast Cancer Foundation has funded CSHL's innovative breast cancer research, led by Dr. Senthil Muthuswamy, to develop alternative treatment strategies for early-stage breast cancer. The foundation aims to identify genetic differences between benign and malignant lesions to prevent cancer progression.
Researchers identified three microRNA molecules that suppress the spread of breast cancer. Restoring these molecules reduces the ability of cancer cells to proliferate and migrate. The study adds to the growing list of cellular targets for drugs designed to prevent breast cancer metastasis.
A study by Memorial Sloan-Kettering Cancer Center identifies a group of microRNA molecules that control genes causing breast cancer metastasis. The loss of these microRNAs allows cancer cells to migrate and grow more rapidly, leading to increased risk of lung and bone metastasis.
A randomized clinical trial found that adding docetaxel to anthracycline-based chemotherapy improved disease-free survival in breast cancer patients. The study showed a 4% increase in five-year disease-free survival rates, with patients receiving sequential docetaxel after doxorubicin having the best outcomes.
The study found significant variation in breast cancer risk among BRCA1 and BRCA2 carriers, with younger age at diagnosis associated with increased risk for relatives. The research highlights the need for accurate estimation of risks and tailored interventions.
A new study analyzing over 2,000 women found that BRCA1 and BRCA2 carrier status varies significantly in relation to breast cancer incidence. The research highlights the importance of considering additional genetic factors beyond known mutations when assessing risk.
A new study found that racial disparities in cancer care have persisted despite efforts to mitigate them. Black patients are significantly less likely than white patients to receive therapy for certain types of cancer, including lung, breast, colon, and prostate cancer.
A recent study by Yale researchers found significant racial disparities in cancer therapy, with black patients less likely than white counterparts to receive treatment for various cancers. Despite efforts to improve access to care, the disparities persisted, highlighting the need for continued work to address these issues.
Research from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) found that chemotherapy safely reduced recurrence, breast cancer mortality, and death from any cause in women with hormone-resistant breast cancer. The study showed a 10-year risk reduction of 25% in younger women and 39% in women aged 50-69 years.
Research published in the Journal of Clinical Oncology found that Ashkenazi Jewish women with BRCA1 or BRCA2 gene mutations have a significantly longer survival rate compared to those without these mutations. After up to nine years of follow-up, carriers were 28% less likely to die from ovarian cancer.
A study found that targeted digital mammography screening can be cost-effective for younger women with dense breasts, while conventional film mammography may be more effective for older women. Additionally, labeling epinephrine as a dose or ratio affected dosing errors among doctors.
Researchers at the Salk Institute found that early-stage breast cancer cells with high motility pose an increased risk of metastasis. These cells can wander along milk ducts and seed new tumors within the same breast, suggesting a need for earlier intervention.
Researchers discovered that cone-beam breast CT provides exceptional tissue contrast and can reduce examination time with comparable radiation dose to conventional 2D mammography. The study found well-resolved images of skin, adipose, and glandular regions, as well as clear detection of microcalcifications within cancers.
The study showed significant benefits of Avastin with Taxol in treating metastatic breast cancer, nearly doubling the time between chemotherapy initiation and tumor progression. This achievement demonstrates Avastin's potential as an antiangiogenic agent in breast cancer therapy.
A large clinical trial found that bevacizumab significantly prolongs progression-free survival for women with recurrent breast cancer when combined with chemotherapy. The study showed a doubling of delay in worsening of the disease and improved remission rates compared to chemotherapy alone.
Breast cancer patients who received tamoxifen or chemotherapy had a reduced risk of developing a second cancer in the other breast. Chemotherapy was associated with a 43% risk reduction, lasting up to 10 years, while tamoxifen use resulted in a 34% risk reduction that persisted for five years.
A genetic mutation known to affect Ashkenazi Jewish breast cancer patients is also prevalent among Hispanic and young African-American women. Research found that 3.5% of Hispanic women had the BRCA1 mutation, while 16.7% of African-American women under 35 did so.
The study found that anthracycline-based chemotherapy improves disease-free and overall survival rates more than non-anthracycline-based regimens for women with HER2-positive tumors. However, the treatment showed no significant benefit for patients with HER2-negative breast cancer.
Most general surgeons fail to discuss breast reconstruction with breast cancer patients before surgery. Researchers found only 33% of eligible patients had this conversation. Younger, more educated patients were more likely to have the discussion, leading to greater willingness to consider mastectomy.
A study published in Journal of Clinical Oncology found that nearly 50% of women over 65 with early stage hormone-positive breast cancer discontinue Tamoxifen treatment before five years. Factors predicting premature discontinuation include age, medical illnesses, and lack of radiation after surgery.
A new study estimated the costs of providing comprehensive screening and diagnostic services to under- or uninsured, low-income women. The median cost of screening a woman for breast cancer was $94, while the cost per detected case was $10,566. For cervical cancer, these costs were $56 and $13,340, respectively.
A new study from the University of Michigan Comprehensive Cancer Center found that only a third of breast cancer patients discussed reconstruction options with their surgeon. Women who did discuss reconstruction were four times more likely to choose a mastectomy, highlighting the importance of informed decision-making in surgical choices.
A microchip-based device, called the CTC-chip, can isolate, enumerate, and analyze circulating tumor cells from blood samples. The device was tested on 68 patients with five different types of tumors and showed a sensitivity rating of 99%, accurately monitoring response to treatment.
Researchers at CSHL have identified and repressed breast cancer stem cells in mouse tissue by manipulating microRNAs, suggesting a potential therapeutic target for breast cancer treatment. The study found that the delivery of the microRNA let-7 to breast-tissue cells can help distinguish stem-like tumor-initiating cells from other cells.
Researchers at the University of Pennsylvania have identified that dioxin targets the mitochondria, disrupting normal cellular function and promoting tumor progression. The study's findings suggest that understanding this mechanism could lead to new ways to block the propagation of mitochondrial stress signaling and inhibit cancer growth.
A combination of lapatinib and capecitabine significantly shrinks brain metastases in patients with aggressive HER2-positive breast cancer, with 10 patients experiencing a 50% reduction. The study's findings offer new hope for treatment options for women with advanced breast cancer who develop brain metastases.
A survey of 367 women with advanced breast cancer underscores the significance of emotional and educational needs, with psychosocial support identified as a high priority. The study also reveals dissatisfaction with treatment experiences and highlights the importance of internet access as an information resource for patients.
Two studies from Mayo Clinic found that ER/PR negative breast cancers have the worst overall outcomes when spreading to the brain, resulting in shorter median survival times. Women with triple negative tumors and HER2+ tumors without estrogen or progesterone receptors have poor outcomes due to aggressive brain metastasis.
A Mayo Clinic program has reduced delays between abnormal mammograms and diagnosis, improving outcomes for women with cancer. The clinic's multidisciplinary breast clinic helped overcome barriers such as lack of transportation and childcare, providing timely care to underserved women.
Researchers found that grade 2 and 3 tumors are more common in HER2+ and triple negative cancers, which have a higher risk of growth and relapse. Cancer came back frequently in these subtypes, with a death rate higher in triple negative breast cancer.
A new study published by Mayo Clinic researchers found that Herceptin helps women with HER2+ type of breast cancer independent of whether they have extra copies of chromosome 17. The analysis showed significant benefits for patients with polysomy 17, including a disease-free survival rate of 89% after three years of treatment.
The ATAC trial confirms anastrozole's superior efficacy over tamoxifen, with increased disease-free survival and reduced cancer recurrence. Long-term benefits of anastrozole treatment persist even after completion.
A new study reveals secretoneurin's neuroprotective role in a rat model of stroke. SN treatment improved survival of primary brain cell cultures and reduced cerebral tissue death in rats with ischemia-induced stroke.
A new survey from Michigan Medicine suggests that when women are told their risk of breast cancer is above average, they're more likely to take a hypothetical pill and overestimate its benefits. The study highlights the importance of considering individual risk information when making medical decisions.
The CTRC-AACR San Antonio Breast Cancer Symposium combines basic, translational, and clinical research to advance breast cancer research. The symposium aims to attract thought-leaders and high-quality papers in basic and translational breast cancer research.
Researchers discovered a genetic switch that regulates critical properties of cancer stem cells using microRNAs. Activating this switch, let-7, can push cancer stem cells to differentiate and lose their tumorigenic abilities, offering a novel approach to targeting these cells with therapeutic RNAs.
A definitive study of 15 randomized trials found that high-dose chemotherapy and autologous stem cell transplantation had no overall survival benefit for women with node-positive breast cancer. However, there was a slight benefit in relapse-free survival.
A nationwide study found that diagnostic mammogram accuracy depends on the radiologist reading it, with varying sensitivity and false-positive rates. Radiologists based at academic medical centers or spending most time on breast imaging performed more accurately.
A study published in the Journal of the National Cancer Institute found that diagnostic mammogram readings vary extensively by radiologist, with no explanation for the variation. Radiologists' performance was influenced by their experience, affiliation, and time spent interpreting mammograms.
A recent study has identified a link between BRCA1 mutations and the loss of the tumor suppressor gene PTEN in breast cancer. This discovery opens up new avenues for treating aggressive forms of breast cancer by targeting proteins in the PTEN pathway.
Research from the American Association for Cancer Research links weight gain and diabetes to increased risks of various cancers. Women with diabetes are 1.5 times more likely to develop colorectal cancer, while those with high C-peptide levels face a risk of death nearly three times higher than women with lower levels.
In a study of 79 women with breast cancer, breast MRI revealed important diagnostic information altering treatment plans in 20 percent of cases. The imaging modality detected additional cancers, discovered cancer in the opposite breast, or determined tumors were larger than expected.
Researchers have found that exposure to a common household chemical, butyl benzyl phthalate (BBP), can cause genomic changes in the mammary gland of rats. The study suggests that this could potentially lead to breast cancer, highlighting the need for further research.
A new marker, ALDH1, has been identified that can be used to detect and characterize cancer stem cells in breast tumors. These cells are responsible for fueling a tumor's growth and are linked to worse outcomes.
A study by American Cancer Society researchers found significant disparities in breast cancer diagnosis, particularly among uninsured and African American women. They are more likely to miss axillary lymph node assessments, which help determine stage and guide treatment decisions.
Researchers at Karolinska Institute have identified a new source of dopamine cells that provided marked benefit when transplanted into mice with Parkinson's-like disease. Wnt5a-treated neural stem cells may be an efficient and safe source for DA cell replacement therapy in individuals with PD.
Direct-to-consumer genetic testing poses risks of misleading patients and physicians due to lack of regulation. Physicians recommend consulting with doctors before ordering tests, as results may not be clinically valid or accurately interpreted.
A recent study found racial discrepancies in breast cancer tumor gene profiles, suggesting inflammation plays a stronger role in development and progression in African-American women. African-American breast cancer patients tend to have a greater prevalence of an aggressive form of cancer less likely to respond to hormone therapy.
A recent study by McGill researchers found that the enzyme focal adhesion kinase (FAK) is crucial for tumour progression from a pre-malignant to a malignant state in the mammary tumour system. The discovery opens up new avenues for developing targeted treatments against breast cancer.
Scientists at Jefferson Medical College have used PET imaging to observe hyperactive breast cancer genes in laboratory animals, marking a breakthrough in detecting and classifying cancer. This technology may help physicians identify breast tumors as early as possible and determine the appropriate treatment.